Affymetrix's Q4 Revenues Slide 6.5 Percent as Profit Plummets 72 Percent | GenomeWeb
NEW YORK (GenomeWeb News) —Affymetrix today said fourth-quarter revenues decreased 6.5 percent as R&D spending remained flat and profit plummeted 72 percent.
Total receipts for the three months ended Dec. 31, 2006, decreased to $104.2 million from $111.4 million year over year.
Product and product-related revenue decreased 9.5 percent to $95 million; royalties and "other" revenue increased 115 percent to $6.6 million; and receipts from Perlegen slid 5.5 percent to $2.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.